Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "NS-Pharma"

52 News Found

Merck completes $5.8 billion acquisition of Terns Pharma
News | May 07, 2026

Merck completes $5.8 billion acquisition of Terns Pharma

At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia


Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals
News | April 08, 2026

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701


Marksans Pharma receives USFDA approval for Benzonatate capsules
Drug Approval | April 02, 2026

Marksans Pharma receives USFDA approval for Benzonatate capsules

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract


SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
Digitisation | March 02, 2026

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions


Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets
Drug Approval | November 24, 2025

Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets

Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea


Marksans Pharma's Goa unit clears FDA inspection
News | November 10, 2025

Marksans Pharma's Goa unit clears FDA inspection

The said inspection concluded with Zero Form 483 observation


Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets
News | November 06, 2025

Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets

Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women


Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
News | August 13, 2025

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent


Briefs: Nectar Lifesciences, Cipla and Marksans Pharma
News | August 12, 2025

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug


Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
News | May 21, 2025

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24